Trial Profile

A Phase 1b/2a Study to Evaluate the Safety of CMTX-101 in Combination with Inhaled Antibiotics in People with Cystic Fibrosis Chronically Infected with Pseudomonas Aeruginosa

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2025 According to Clarametyx Biosciences media release, the full study enrollment is expected by end of 2025.
16 Jun 2025 Interim Results(n=21) presented in the Clarametyx Biosciences media release.
28 Jan 2025 According to Clarametyx Biosciences media release, has received investment from the Kineticos AMR Accelerator Fund, extending its Series A funding round from 2024. This investment will support the company's pipeline, including the ongoing CMTX-101 trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com